Women with persistent human papillomavirus (HPV) infections have a high risk of developing cervical cancer (CaCx). HPV-16 alone accounts for more than 60% of CaCx worldwide. Most of the HPV infections are transient and only a subset of women develop persistent HPV-16 infection. Many studies have shown associations of different human leukocyte antigen (HLA) alleles with HPV-mediated CaCx, but there are only a few studies globally that relate to persistent HPV-16 infection. Furthermore, such studies from India are sparse. Hence, we investigated the association of HLA-A, B, DRB, and DQB alleles with persistent HPV-16 infection and HPV-16-positive CaCx in south India (Tamil Nadu). HPV-16 persistent infection was observed in 7% of normal women. A total of 50 women with HPV-16-positive CaCx, 21 women with HPV-16 persistent infection, and 74 HPV-16-negative normal women were recruited for this study. Low-resolution typing of HLA-A, B, DRB, and DQB alleles was performed. HLA-B*44 and DRB1*07 showed a significant association with persistent HPV-16 infection (odds ratio, p-value = 26.3, 0.03 and 4.7, 0.01, respectively). HLA-B*27 and DRB1*12 were significantly associated with both HPV-16+ CaCx and persistent HPV-16 infection (23.8, 0.03; 52.9, 0.01; 9.8, 0.0009; and 13.8, 0.009; respectively). HLA-B*15 showed a negative association with HPV-16-positive CaCx (0.1, 0.01), whereas DRB1*04 exhibited protection to both HPV-16-positive CaCx and persistent HPV-16 infection (0.3, 0.0001 and 0.1, 0.0002, respectively). Thus, we show HLA allelic association with HPV-16 infection in Tamil Nadu. Larger studies on high-resolution HLA typing coupled with HPV-16 genome diversity will offer further insights into host/pathogen genome coevolution.
ArunKumarG, Soria-HernanzDF, KavithaVJ, et al.Population differentiation of southern Indian male lineages correlates with agricultural expansions predating the caste system. PLoS One, 2012; 7:e50269.
3.
BahlsL, YamakawaR, ZanãoK, et al.Human leukocyte antigen class I and class II polymorphisms and serum cytokine profiles in cervical cancer. Int J Mol Sci, 2017; 18:1478.
4.
BalakrishnanK, PitchappanR, SuzukiK, et al.HLA affinities of Iyers, a Brahmin population of Tamil Nadu, south India. Hum Biol, 1996:523–537.
5.
BhaskaranM, and ArunKumarG. A meta-analysis of association of human leukocyte antigens A, B, C, DR and DQ with human papillomavirus 16 infection. Infect Genet Evol, 2019; 68:194–202.
6.
BhattacharyaP, and SenguptaS. Predisposition to HPV16/18-related cervical cancer because of proline homozygosity at codon 72 of p53 among Indian women is influenced by HLA-B* 07 and homozygosity of HLA-DQB1* 03. Tissue Antigens, 2007; 70:283–293.
7.
BontkesHJ, van DuinM, de GruijlTD, et al.HPV 16 infection and progression of cervical intra-epithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequence variants. Int J Cancer, 1998; 78:166–171.
8.
BruniL, DiazM, CastellsaguéM, et al.Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis, 2010; 202:1789–1799.
9.
BunceM, Fanning G and WelshK. Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens, 1995; 45:81–90.
10.
BunceM, TaylorCJ, and WelshKI. Rapid HLA-DQB typing by eight polymerase chain reaction amplifications with sequence-specific primers (PCR-SSP). Hum Immunol, 1993; 37:201–206.
11.
BurkRD, Harari A and ChenZ. Human papillomavirus genome variants. Virology, 2013; 445:232–243.
12.
ByunJM, JeongDH, KimYN, et al.Persistent HPV-16 infection leads to recurrence of high-grade cervical intraepithelial neoplasia. Medicine, 2018; 97:e13606.
13.
ChanPK, CheungJL, CheungTH, et al.HLA-B alleles, high-risk HPV infection and risk for cervical neoplasia in southern Chinese women. Int J Cancer, 2006; 118:1430–1435.
14.
CliffordGM, TenetV, GeorgesD, et al.Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: whole viral genome sequences from 7116 HPV16-positive women. Papillomavirus Res, 2019; 7:67–74.
15.
Das GhoshD, MukhopadhyayI, BhattacharyaA, et al.Impact of genetic variations and transcriptional alterations of HLA class I genes on cervical cancer pathogenesis. Int J Cancer, 2017; 140:2498–2508.
16.
DavidsonEJ, DavidsonJA, SterlingJC, et al.Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res, 2003; 63:400–403.
17.
de MartelC, PlummerM, VignatJ, et al.Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer, 2017; 141:664–670.
18.
de VilliersE-M, FauquetC, BrokerTR, et al.Classification of papillomaviruses. Virology, 2004; 324:17–27.
19.
DillonS, SasagawaT, CrawfordA, et al.Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2. J Gen Virol, 2007; 88:803–813.
20.
DuttaS, ChakrabortyC, MandalRK, et al.Persistent HPV16/18 infection in Indian women with the A-allele (rs6457617) of HLA-DQB1 and T-allele (rs16944) of IL-1β− 511 is associated with development of cervical carcinoma. Cancer Immunol Immunnother, 2015; 64:843–851.
21.
EgawaN, EgawaK, GriffinH, et al.Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses, 2015; 7:3863–3890.
22.
ErlichHA. HLA polymorphism and disease susceptibility. In: PeltzG, ed. Computational Genetics and Genomics: tools for Understanding Disease. Totowa, New Jersey: Humana Press, 2005:255–268.
23.
GokhaleP, KerkarS, TongaonkarH, et al.Variations in immunogenetics, human papillomavirus (HPV) infection & predisposition to cervical cancer in Indian women. Indian J Med Res, 2014; 140:S36.
24.
GorskovaE and Sevost'ianovE. Associations of HLA class I haplotype antigens with various patterns of keratoconus. Vestn Oftalmol, 1997; 113:31–33.
25.
Hernández-HernándezDM, Cerda-FloresRM, Juárez-CedilloT, et al.Human leukocyte antigens I and II haplotypes associated with human papillomavirus 16-positive invasive cervical cancer in Mexican women. Int J Gynecol Cancer, 2009; 19:1099–1106.
26.
HoffmanSR, LeT, LockhartA, et al.Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review. Int J Cancer, 2017; 141:8–23.
27.
JacobsM, de Roda HusmanA, Van den BruleA, et al.Group-specific differentiation between high-and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol, 1995; 33:901–905.
28.
KohaarI, HussainS, ThakurN, et al.Association between human leukocyte antigen class II alleles and human papillomavirus-mediated cervical cancer in Indian women. Hum Immunol, 2009; 70:222–229.
29.
KonnoR, TamuraS, DobbelaereK, et al.Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a phase 2 double-blind, randomized controlled trial. Int J Gynecol Cancer, 2010; 20:847–855.
30.
KoshiolJ, LindsayL, PimentaJM, et al.Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol, 2008; 168:123–137.
31.
KrulE, SchipperR, SchreuderGT, et al.HLA and susceptibility to cervical neoplasia. Hum Immunol, 1999; 60:337–342.
32.
KudohA, SatoS, ItamochiH, et al.Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia. Int J Clin Oncol, 2016; 21:580–587.
33.
La TorreG, De WaureC, ChiaradiaG, et al.HPV vaccine efficacy in preventing persistent cervical HPV infection: a systematic review and meta-analysis. Vaccine, 2007; 25:8352–8358.
34.
LiN, FranceschiS, Howell-JonesR, et al.Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer, 2011; 128:927–935.
35.
LiuH, WeiX, XieZ, et al.Cervical human papillomavirus among 19 753 women attending gynecological department of a major comprehensive hospital in north Anhui China 2013-2016: implication for cervical cancer screening and prevention. J Med Virol, 2019; 91:698–706.
36.
LongworthMS, and LaiminsLA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev, 2004; 68:362–372.
37.
MadeleineMM, BrumbackB, Cushing-HaugenKL, et al.Human leukocyte antigen class II and cervical cancer risk: a population-based study. J Infect Dis, 2002; 186:1565–1574.
38.
ManglaniMV, GabhaleYR, LalaMM, et al.HLA-B* 5701 allele in HIV-infected Indian children and its association with Abacavir hypersensitivity. Indian Pediatr, 2018; 55:140–141.
39.
MillerS, DykesD, and PoleskyH. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res, 1988; 16:1215.
40.
MotaF, RaymentN, ChongS, et al.The antigen-presenting environment in normal and human papillomavirus (HPV)-related premalignant cervical epithelium. Clin Exp Immunol, 1999; 116:33–40.
41.
OlerupO, and ZetterquistH. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens, 1992; 39:225–235.
42.
PimenoffVN, de OliveiraCM, and BravoIG. Transmission between archaic and modern human ancestors during the evolution of the oncogenic human papillomavirus 16. Mol Biol Evol, 2016; 34:4–19.
43.
PitchappanRM. Castes, migration, immunogenetics and infectious diseases in south India. Community Genet, 2002; 5:157–161.
44.
PitchappanRM. Not all the infected develop the disease—a “Lotus and Cactus” model. Infect Genet Evol, 2016; 40:303–309.
45.
PitchappanRM, KakkanaiahV, RajashekarR, et al.HLA antigens in south India: I. Major groups of Tamil Nadu. Tissue Antigens, 1984; 24:190–196.
46.
PontilloA, BricherP, LealV, et al.Role of inflammasome genetics in susceptibility to HPV infection and cervical cancer development. J Med Virol, 2016; 88:1646–1651.
47.
QiuX, ZhangF, ChenD, et al.HLA-B* 07 is a high risk allele for familial cervical cancer. Asian Pac J Cancer Prev, 2011; 12:2597–2600.
48.
RadleyD, SaahA, and StanleyM. Persistent infection with human papillomavirus 16 or 18 is strongly linked with high-grade cervical disease. Hum Vaccin Immunother, 2016; 12:768–772.
49.
RajasekarR, KakkanaiahV, and PitchappanR. HLA antigens in South India: II. Selected caste groups of Tamil Nadu. Tissue Antigens, 1987; 30:113–118.
50.
RamanakumarAV, GoncalvesO, RichardsonH, et al.Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis, 2010; 10:326.
51.
RathikaC, MuraliV, DhivakarM, et al.Susceptible and protective associations of HLA alleles and haplotypes with cervical cancer in South India. Asian Pac J Cancer Prev, 2016; 17:2491–2497.
52.
RodríguezAC, SchiffmanM, HerreroR, et al.Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst, 2008; 100:513–517.
53.
SaitoM, OkuboM, HirataR, et al.Association of human leukocyte antigen and T cell message with human papillomavirus 16-positive cervical neoplasia in Japanese women. Int J Gynecol Cancer, 2007; 17:1314–1321.
54.
Sastre-GarauX, LosteMN, Vincent-SalomonA, et al.Decreased frequency of HLA-DRB 1* 13 alleles in Frenchwomen with HPV-positive carcinoma of the cervix. Int J Cancer, 1996; 69:159–164.
55.
SeshasubramanianV, SoundararajanG, and RamasamyP. Human leukocyte antigen A, B and Hepatitis B infection outcome: a meta-analysis. Infect Genet Evol, 2018; 66:392–398.
56.
ShanmugasundaramS, and YouJ. Targeting persistent human papillomavirus infection. Viruses, 2017; 9:229.
57.
SkinnerSR, SzarewskiA, RomanowskiB, et al.Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet, 2014; 384:2213–2227.
58.
SoKA, KimSA, LeeYK, et al.Risk factors for cytological progression in HPV 16 infected women with ASC-US or LSIL: the Korean HPV cohort. Obstet Gynecol Sci, 2018; 61:662–668.
59.
SreedeviA, JavedR, and DineshA. Epidemiology of cervical cancer with special focus on India. Int J Womens Health, 2015; 7:405.
60.
StanleyM. Immune responses to human papilloma viruses. Indian J Med Res, 2009; 130:266.
61.
SyrjänenK, NurmiT, MäntyjärviR, et al.HLA types in women with cervical human papillomavirus (HPV) lesions prospectively followed up for 10 years. Cytopathology, 1996; 7:99–107.
62.
TeamRC. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2013.
63.
TonksS, MarshS, BunceMM, et al.Molecular typing for HLA class I using ARMS-PCR: further developments following the 12th International Histocompatibility Workshop. Tissue Antigens, 1999; 53:175–183.
64.
TorreLA, IslamiF, SiegelRL, et al.Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev, 2017; 26:444–457.
65.
WangS, WeiH, WangN, et al.The prevalence and role of human papillomavirus genotypes in primary cervical screening in the northeast of China. BMC Cancer, 2012; 12:160.
66.
WangSS, WheelerCM, HildesheimA, et al.Human leukocyte antigen class I and II alleles and risk of cervical neoplasia: results from a population-based study in Costa Rica. J Infect Dis, 2001; 184:1310–1314.
67.
WestrichJA, WarrenCJ, and PyeonD. Evasion of host immune defenses by human papillomavirus. Virus Res, 2017; 231:21–33.
68.
World Health Organization. Cervical Cancer, 2018. https://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/ (accessed August1, 2019).
69.
WieczorekM, AbualrousET, StichtJ, et al.Major histocompatibility complex (MHC) class I and MHC class II proteins: conformational plasticity in antigen presentation. Front Immunol, 2017; 8:292.
70.
XiLF, KiviatNB, HildesheimA, et al.Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst, 2006; 98:1045–1052.
71.
ZehbeI, MytilineosJ, WikströmI, et al.Association between human papillomavirus 16 E6 variants and human leukocyte antigen class I polymorphism in cervical cancer of Swedish women. Hum Immunol, 2003; 64:538–542.
72.
ZhuFC, ChenW, HuYM, et al.Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled trial. Int J Cancer, 2014; 135:2612–2622.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
